Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver

Abstract

Patients with cutaneous melanoma can develop in-transit metastases (ITM), most often localized to limbs. For patients with uveal melanoma that develop metastatic disease, the overall majority develop isolated liver metastases. For these types of metastases, regional cancer therapies have evolved as effective treatments. Isolated limb perfusion (ILP), isolated limb infusion (ILI), isolated hepatic perfusion (IHP) and percutaneous hepatic perfusion (PHP) achieve a high local concentration of chemotherapy with minimal systemic exposure. This review discusses the mechanism and available literature on locoregional treatment modalities in the era of modern immunotherapy.

Inhibiting IL11RA to mitigate hepatic metastasis in skin cutaneous melanoma: Comprehensive insights from in vitro and in vivo investigations

“…Despite constituting only 4% of skin cancers, SKCM is responsible for a staggering 75% of skin cancer‐related deaths, underscoring the critical need for early detection and intervention 3 . While advancements have improved outcomes, a subset of patients presents with metastatic disease at diagnosis or later develops metastasis, with the liver being a common site 4,5 . Liver metastases, occurring in 10%−20% of cutaneous melanoma patients, present unique challenges, emphasizing the urgency for innovative treatment strategies 6,7 …”

“…3 While advancements have improved outcomes, a subset of patients presents with metastatic disease at diagnosis or later develops metastasis, with the liver being a common site. 4,5 Liver metastases, occurring in 10%−20% of cutaneous melanoma patients, present unique challenges, emphasizing the urgency for innovative treatment strategies. 6,7 Genetic analyses have identified frequent chromosomal loss at 9p13-p22 in melanoma, implicating Interleukin 11 receptor alpha (IL11RA) as a pivotal player encoded in this region.…”

“… 3 While advancements have improved outcomes, a subset of patients presents with metastatic disease at diagnosis or later develops metastasis, with the liver being a common site. 4 , 5 Liver metastases, occurring in 10%−20% of cutaneous melanoma patients, present unique challenges, emphasizing the urgency for innovative treatment strategies. 6 , 7 …”

Repeated use of hybrid isolated chemoperfusion with melphalan in non-resectable liver malignancy

“…Изолированная химиоперфузия печени -метод регионарной химиотерапии, суть которого заключается в выключении печени из системного кровотока, создании искусственного контура кровообращения печени с высокой концентрацией химиотерапевтического агента (как правило, мелфалана) на ограниченный период времени и отмывании печени от химиопрепарата перед включением в системный кровоток. Различные исследователи сообщают о частоте объективных ответов образований после ИХП, равной 37-52 % при метастазах увеальной меланомы, 50-60 %при метастатическом поражении печени при прогрессировании колоректального рака, 45-55 %при холангиокарциноме печени [5][6][7][8][9][10][11].…”

Intralesional and Infusional Updates for Metastatic Melanoma

“…Comparison of isolated limb perfusion and isolated limb infusion techniques[4,[70][71][72][73][74]. http://creativecommons.org/licenses/by/4.0/ (accessed on 1 April 2024) (minimal changes made).…”